期刊论文详细信息
Frontiers in Nutrition
Bornlisy Attenuates Colitis-Associated Colorectal Cancer via Inhibiting GPR43-Mediated Glycolysis
Wenyue Yan1  Ping Chen1  Shuli Zhao2  Tingting Wang3  Yayi Hou3  Shuping Qiao3  Xia Lu3  Chen Peng3  Junxing Qu3  Zhen Xu3 
[1] Department of Oncology, Yancheng First Hospital, Affiliated Hospital of Nanjing University Medical School, The First People's Hospital of Yancheng, Yancheng, China;General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, China;The State Key Laboratory of Pharmaceutical Biotechnology, Division of Immunology, Medical School, Nanjing University, Nanjing, China;
关键词: colitis-associated colon cancer;    probiotic;    metabolism reprogramming;    glycolysis;    GPR43;   
DOI  :  10.3389/fnut.2021.706382
来源: DOAJ
【 摘 要 】

There is evidence that probiotics have a broad antitumor effect in colorectal cancer (CRC). However, the mechanism remains obscure. Here, we investigated the effect of Bornlisy (BO)-cocktails of three probiotics on colitis-associated colon cancer (CAC) and the underlying mechanism. The treatment of CAC mice with BO resulted in decreased tumor loads as compared with their counterparts. BO also inhibited the proliferation and metastasis of CRC cells in vitro. Furthermore, BO inhibited cell proliferation through downregulating glycolysis. Activating glycolysis reversed the protective role of BO in the CAC mice. Mechanically, BO administration promoted the activation of GPR43, followed by its downstream PLC-PKC-ERK pathway, which led to decreased glucose metabolism. These results suggest that BO may provide an intervention strategy for CRC therapy, while GPR43 is a potential targeting receptor during the BO treatment.

【 授权许可】

Unknown   

  文献评价指标  
  下载次数:0次 浏览次数:0次